Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study.
Michael J NathensonJunxiao HuRavin RatanNeeta SomaiahRobert HsuPeter Joseph DeMariaHeath W CatoeAngela PangTy K SubhawongBehrang AminiKevin SweetKatharina FeisterKaran MalikJyothi JagannathanMarta Braschi-AmirfarzanJamie SherenYupanqui A CaldasCristiam Moreno TellezAndrew E RosenbergAlexander J F LazarRobert G MakiPasquale BenedettoJonathan CohenJonathan C TrentVinod RaviShreyaskumar PatelBreelyn A WilkyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Mutation subtype did not affect responses to specific systemic therapies. APC mutations and nonextremity desmoid tumor locations remain prognostic for worse outcomes, and earlier initiation of systemic therapy for these higher-risk desmoid tumors should be prospectively evaluated. See related commentary by Greene and Van Tine, p. 3911.